Puma Biotechnology reported $109.59M in Current Liabilities for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Agios Pharmaceuticals AGIO:US $ 59.83M 1.93M
Cerulean Pharma CERU:US $ 16.05M 0.15M
Daiichi Sankyo 4568:JP Y 355195M 19149M
Mirati Therapeutics MRTX:US $ 123.57M 20.09M
Novartis NOVN:VX SF 30208M 328M
Sangamo Biosciences SGMO:US $ 118.53M 9.36M
Spectrum Pharmaceuticals SPPI:US $ 39.21M 14.02M
Tg Therapeutics TGTX:US $ 65.38M 22.27M